← Back to Screener
Skye Bioscience, Inc. Common Stock (SKYE)
Price$0.75
Favorite Metrics
Price vs S&P 500 (26W)-59.04%
Price vs S&P 500 (4W)9.04%
Market Capitalization$25.80M
All Metrics
Book Value / Share (Quarterly)$0.60
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.29
Price vs S&P 500 (YTD)0.42%
Gross Margin (TTM)39.29%
Net Profit Margin (TTM)-3.57%
EPS (TTM)$-1.41
10-Day Avg Trading Volume0.21M
EPS Excl Extra (TTM)$-1.41
EPS (Annual)$-1.41
ROI (Annual)-279.29%
Gross Margin (Annual)35.29%
Cash / Share (Quarterly)$0.80
ROA (Last FY)-197.52%
EBITD / Share (TTM)$-1.44
ROE (5Y Avg)-346.11%
Operating Margin (TTM)-7.14%
Cash Flow / Share (Annual)$-1.29
P/B Ratio1.29x
P/B Ratio (Quarterly)1.20x
Net Income / Employee (Annual)$-5
Net Interest Coverage (TTM)-45.68x
ROA (TTM)-119.89%
EPS Incl Extra (Annual)$-1.41
Current Ratio (Annual)3.30x
Quick Ratio (Quarterly)3.24x
3-Month Avg Trading Volume0.54M
52-Week Price Return-40.99%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.14
P/S Ratio (Annual)75.89x
Asset Turnover (Annual)2.27x
52-Week High$5.75
EPS Excl Extra (Annual)$-1.41
CapEx CAGR (5Y)-8.80%
26-Week Price Return-55.06%
Quick Ratio (Annual)3.24x
13-Week Price Return-17.85%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.30x
Enterprise Value$19.092
Asset Turnover (TTM)1.93x
Book Value / Share Growth (5Y)-36.64%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)0.00%
Cash / Share (Annual)$0.80
3-Month Return Std Dev74.31%
Net Income / Employee (TTM)$-5
ROE (Last FY)-279.29%
Net Interest Coverage (Annual)-44.71x
EPS Basic Excl Extra (Annual)$-1.41
Receivables Turnover (TTM)9.33x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.41
ROI (TTM)-143.59%
P/S Ratio (TTM)92.15x
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$-0.82
Price vs S&P 500 (52W)-70.82%
Year-to-Date Return3.07%
5-Day Price Return6.50%
EPS Normalized (Annual)$-1.41
ROA (5Y Avg)-169.91%
Net Profit Margin (Annual)0.00%
Month-to-Date Return25.69%
Cash Flow / Share (TTM)$-9.31
EBITD / Share (Annual)$-1.44
Operating Margin (Annual)0.00%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-130.36%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.41
P/TBV (Quarterly)11.06x
P/B Ratio (Annual)1.20x
Pretax Margin (TTM)-3.57%
Book Value / Share (Annual)$0.60
Price vs S&P 500 (13W)-18.54%
Beta2.95x
Revenue / Share (TTM)$0.00
ROE (TTM)-143.59%
52-Week Low$0.57
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.07
4.07
4.07
4.07
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
SKYESkye Bioscience, Inc. Common Stock | 92.15x | — | 39.29% | — | $0.75 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Skye Bioscience is a San Diego-based pharmaceutical company developing CB1 receptor-targeted therapies for metabolic and inflammatory disorders. Lead candidates in Phase 2 are nimacimab for obesity and SBI-100 Ophthalmic Emulsion for glaucoma and ocular hypertension. The platform also targets fibrotic and neurodegenerative diseases.